Further, the injection of soluble CX3CL1 was found to reduce microglia activation and improve the time taken to reach coma, indicating that an imbalance of CCL2 and CX3CL1 expression may be driving the activation of microglia during Type A HE [75]. The gene discussed is CCL2; the disease is hereditary elliptocytosis.